ExcellGene SA, privately held and founded 2001, has announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership of public, private, philanthropic and civil society organizations founded to develop vaccines against future epidemics.
The consortium partnership strives to advance a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern (VoCs) as well as other Betacoronaviruses. ExcellGene will produce complex chimeric Spike antigens using its engineered CHOExpress-cell based technology. The Swiss company will use insights from several scientific and technical disciplines along with artificial intelligence to identify the most promising antigenic structure.
